Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. on October 16, 2017. The filing reports the appointment of a new member to the Board of Directors and the associated compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
The primary material change reported is the appointment of Paris Panayiotopoulos to the Board of Directors, effective October 16, 2017. Mr. Panayiotopoulos previously served as President and CEO of ARIAD Pharmaceuticals, Inc. (acquired by Takeda in 2017) and held executive roles at EMD Serono and Eli Lilly.
Compensation and Governance Details
- Compensation: Mr. Panayiotopoulos will receive an initial stock option grant to purchase 61,000 shares, an annual cash retainer of $35,000 (pro-rated for the current year), and future annual stock option grants.
- Indemnification: The Company entered into a standard indemnification agreement with Mr. Panayiotopoulos, covering legal expenses and liabilities arising from his service as a director.
- Regulation FD: A press release announcing the appointment was issued on October 17, 2017.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 61,000 initial option grant.
- Review the Company's standard non-employee director compensation plan for details on future annual option grants.
- Confirm the terms of the indemnification agreement filed as Exhibit 10.15 to the Amendment No. 1 to the Form S-1.
- Assess Mr. Panayiotopoulos's prior experience in biopharmaceutical partnerships and board service.